All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @gabrielhpatino on TikTok · 31s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @gabrielhpatino's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00or three things you need to know when you're an osmotic.
  2. 0:03Number one, stay well hydrated, right?
  3. 0:05You may forget to drink because you don't have much appetite,
  4. 0:08but that's important because you wanna prevent
  5. 0:10also constipation.
  6. 0:13Number two, eat plenty of protein.
  7. 0:16You don't wanna lose muscle mass.
  8. 0:19And number three, exercise, precisely to build muscle mass
  9. 0:24and the protein will help you.
  10. 0:26Let us know if you're keeping up with your protein intake,
  11. 0:29okay?

Three things to know about Ozempic: fact-checking the claims

Dr. Patino

TikTok creator

16.6K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide suppress appetite and slow gastric emptying, which creates real risks for inadequate fluid and protein intake during treatment. Clinical trials including the STEP program have documented lean mass loss alongside fat loss, making protein adequacy and resistance exercise genuinely important components of GLP-1 therapy, not optional lifestyle bonuses. Patients should work with their prescriber or a registered dietitian to set specific protein targets and an exercise plan rather than relying on general social media advice.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Three things to know about Ozempic: fact-checking the claims, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Three things to know about Ozempic: fact-checking the claims" from Dr. Patino. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide suppress appetite and slow gastric emptying, which creates real risks for inadequate fluid and protein intake during treatment.

The reason this review is not generic is the source wording and the canonical claim label "glp1 here are three things you should know if you re on ozemp c." In this clip, the useful excerpt is: "or three things you need to know when you're an osmotic." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Clinical guidance from the International Society of Sports Nutrition sets protein targets at 1.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide suppress appetite and slow gastric emptying, which creates real risks for inadequate fluid and protein intake during treatment.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide suppress appetite and slow gastric emptying, which creates real risks for inadequate fluid and protein intake during treatment. Clinical trials including the STEP program have documented lean mass loss alongside fat loss, making protein adequacy and resistance exercise genuinely important components of GLP-1 therapy, not optional lifestyle bonuses. Patients should work with their prescriber or a registered dietitian to set specific protein targets and an exercise plan rather than relying on general social media advice.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide-treated patients lost both fat mass and fat-free mass, making protein and exercise advice clinically relevant, not just wellness tips.
  • Clinical guidance from the International Society of Sports Nutrition sets protein targets at 1.2-1.6g per kilogram of body weight per day for lean mass preservation during weight loss, a specific number the video doesn't provide.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide-treated patients lost both fat mass and fat-free mass, making protein and exercise advice clinically relevant, not just wellness tips.
  • Clinical guidance from the International Society of Sports Nutrition sets protein targets at 1.2-1.6g per kilogram of body weight per day for lean mass preservation during weight loss, a specific number the video doesn't provide.
  • GLP-1 agonists slow gut motility directly through receptor action, meaning constipation risk isn't resolved by hydration alone. Fiber intake and, in some cases, stool softeners are part of the clinical management picture.
  • Nausea and vomiting occur in 20-40% of semaglutide users during dose escalation, compounding the dehydration risk the creator correctly identifies, so tracking fluid intake deliberately is a reasonable practice.
  • Resistance training two to three times per week is the evidence-backed approach for preserving lean mass during GLP-1 therapy. Cardio exercise provides separate metabolic benefits and should not be excluded from the picture.
  • Older adults and people losing weight rapidly on GLP-1 therapy face the highest risk of clinically significant lean mass loss and should prioritize a structured conversation with their prescriber or a registered dietitian about protein and exercise targets.
  • Social media GLP-1 tips can reflect real clinical evidence, as this video largely does, but generic advice is not a substitute for individualized care planning with a qualified provider.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @gabrielhpatino actually say?

The creator laid out three tips for people on semaglutide: stay hydrated because appetite suppression can make you forget to drink, eat plenty of protein to avoid muscle loss, and exercise specifically to build muscle. The hydration advice came with a practical warning about constipation as a motivating reason to keep fluid intake up. Short, punchy, and mostly sensible. But "mostly" is doing some work there, so let's go through each one.

Does the science back this up?

Hydration: yes, with nuance. GLP-1 receptor agonists slow gastric emptying and significantly blunt appetite, which means people genuinely do forget to eat and drink. Nausea and vomiting, reported in roughly 20-40% of semaglutide users in clinical trials, compound fluid losses. The constipation connection is real, documented in the SUSTAIN and STEP trial series. Fluid intake helps motility, so the creator's reasoning is sound even if simplified.

Protein: yes, and this one matters more than the video suggests. A 2023 analysis by Cava et al. in Obesity Reviews found that GLP-1-driven weight loss carries a meaningful risk of lean mass loss, sometimes exceeding what's typical in caloric restriction alone. Higher protein intake, roughly 1.2-1.6g per kilogram of body weight per day according to guidelines from the International Society of Sports Nutrition (Stokes et al., 2018, Journal of the International Society of Sports Nutrition), helps preserve that lean tissue.

Exercise: yes, resistance training in particular. Bray et al. and follow-up work have consistently shown that combining resistance exercise with caloric restriction preserves more lean mass than diet alone. The creator is right to name exercise alongside protein.

What did they get wrong (or right)?

Mostly right, honestly. The three recommendations are evidence-supported and reflect what most obesity medicine clinicians actually tell patients. That said, a few gaps worth naming:

  • "Eat plenty of protein" is vague enough to be unhelpful. Plenty compared to what? Someone eating 40g per day and bumping to 80g is different from someone hitting 120g. The video gives no anchor and that matters clinically.
  • The exercise advice is directionally correct but incomplete. The creator says exercise "to build muscle mass," but cardiovascular exercise has its own role in metabolic health that isn't captured here. Resistance training is the priority for lean mass preservation, but framing it only as muscle-building undersells the full picture.
  • The hydration-to-constipation link is accurate but the mechanism is simplified. GLP-1 agonists slow gut motility directly, not just as a downstream effect of dehydration. Fiber intake is probably as important as fluids here, and the video skips that entirely.

Nothing the creator said was dangerous or factually wrong. It's the omissions that could trip someone up.

What should you actually know?

If you're on a GLP-1 medication, these three tips are a reasonable starting floor, not a ceiling. Protein targets should be specific: most clinical guidance lands between 1.2-1.6g per kilogram of body weight daily, and getting there while appetite-suppressed is genuinely hard. Tracking matters. On exercise, resistance training two to three times per week is the evidence-backed approach for preserving lean mass during GLP-1-assisted weight loss. Walking and cardio are still useful, just for different reasons.

On constipation specifically, hydration helps but fiber, magnesium intake, and sometimes stool softeners are part of the conversation your prescriber should be having with you. If constipation is severe or lasts more than a week, that warrants a clinical check, not just more water.

One thing the video doesn't mention: muscle loss on GLP-1 therapies can happen faster than people expect, particularly in older adults or anyone losing weight rapidly. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average fat-free mass losses alongside fat loss. The protein and exercise advice in this video is a direct, appropriate response to that risk. Credit where it's due.

Bottom line

This is one of the better GLP-1 tip videos circulating on TikTok. The three recommendations are grounded in real clinical evidence. The main issue is precision: "stay hydrated," "eat protein," and "exercise" are correct but generic. Anyone using these as their actual care plan should be having a more specific conversation with their prescriber or a registered dietitian who works with GLP-1 patients. Social media tips are a starting point, not a substitute for individualized guidance.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr. Patino · TikTok creator

16.6K views on this video

Here are three things you should know if you’re on Ozemp*c!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) found?

The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide-treated patients lost both fat mass and fat-free mass, making protein and exercise advice clinically relevant, not just wellness tips.

What does the video say about clinical guidance from the international society of sports nutrition sets?

Clinical guidance from the International Society of Sports Nutrition sets protein targets at 1.2-1.6g per kilogram of body weight per day for lean mass preservation during weight loss, a specific number the video doesn't provide.

What does the video say about glp-1 agonists slow gut motility directly through receptor action, meaning?

GLP-1 agonists slow gut motility directly through receptor action, meaning constipation risk isn't resolved by hydration alone. Fiber intake and, in some cases, stool softeners are part of the clinical management picture.

What does the video say about nausea?

Nausea and vomiting occur in 20-40% of semaglutide users during dose escalation, compounding the dehydration risk the creator correctly identifies, so tracking fluid intake deliberately is a reasonable practice.

What does the video say about resistance training two to three times per week?

Resistance training two to three times per week is the evidence-backed approach for preserving lean mass during GLP-1 therapy. Cardio exercise provides separate metabolic benefits and should not be excluded from the picture.

What does the video say about older adults?

Older adults and people losing weight rapidly on GLP-1 therapy face the highest risk of clinically significant lean mass loss and should prioritize a structured conversation with their prescriber or a registered dietitian about protein and exercise targets.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr. Patino, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.